MAGNESIUM 1-GLYCEROPHOSPHATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C3H7O6P.Mg
Molecular Weight	194.3628
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MAGNESIUM 1-GLYCEROPHOSPHATE

Structure Search

SMILES

[Mg++].OCC(O)COP([O-])([O-])=O

InChI

InChIKey=BHJKUVVFSKEBEX-UHFFFAOYSA-L

InChI=1S/C3H9O6P.Mg/c4-1-3(5)2-9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2

HIDE SMILES / InChI

Molecular Formula	Mg
Molecular Weight	24.305
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C3H7O6P
Molecular Weight	170.0578
Charge	-2
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.nice.org.uk/guidance/esuom4/resources/preventing-recurrent-hypomagnesaemia-oral-magnesium-glycerophosphate-1503234975394501
Curator's Comment: description was created based on several sources, including: http://barnsleybest.nhs.sitekit.net/clinical-support/medicines/prescribing-guidelines/Oral%20Magnesium%20Supplementation%20for%20Hypomagnesaemia.pdf | http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=60240181&typedoc=N | http://www.isaltis.com/en/module/99999689/30/magnesium_glycerophosphate | http://eurekasante.vidal.fr/medicaments/vidal-famille/medicament-ouvima01-UVIMAG-B6.html

Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. Magnesium glycerophosphate is a bioavailable well tolerated source of magnesium. The organic glycerophosphoric anion, by itself, offers very significant nutritional advantages (a source of phosphorus, permeation enhancer). Adverse effects are: diarrhea, abdominal pain.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
magnesium ion homeostasis 70 Target ID: GO:0010960 Sources: http://www.isaltis.com/en/module/99999689/30/magnesium_glycerophosphate	Modulator 828

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypomagnesemia 3 Sources: http://barnsleybest.nhs.sitekit.net/clinical-support/medicines/prescribing-guidelines/Oral%20Magnesium%20Supplementation%20for%20Hypomagnesaemia.pdf https://www.nice.org.uk/guidance/esuom4/resources/preventing-recurrent-hypomagnesaemia-oral-magnesium-glycerophosphate-1503234975394501	Curative		Approved 8429	UVIMAG B6 Approved Use Indicated for the treatment of magnesium deficiencies.

PubMed

Title	Date	PubMed
Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation.	1990	1692533
The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis.	2000 Nov	11136367
Generation of composites for bone tissue-engineering applications consisting of gellan gum hydrogels mineralized with calcium and magnesium phosphate phases by enzymatic means.	2016 Nov	24616374

Patents

Sample Use Guides

In Vivo Use Guide

1-2 tablets three to four times daily (12-32 mmol/day)

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:04:11 GMT 2023` Edited by `admin` on `Fri Dec 15 16:04:11 GMT 2023`
Record UNII	89I3KNZ71G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MAGNESIUM 1-GLYCEROPHOSPHATE

Common Name

English

RAC-GLYCERO-1-PHOSPHATE, MAGNESIUM SALT

Common Name

English

ANHYDROUS MAGNESIUM GLYCEROPHOSPHATE

Common Name

English

GLYCEROL, 1-(DIHYDROGEN PHOSPHATE), MAGNESIUM SALT (1:1)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID00919002